Back to News
Oct 13, 2025 8:00 AM

Immuron Q1 FY26 YoY growth

Sales Highlights (unaudited):

Global



Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)

 

 

 

Australia



Q1 sales AUD$1.6 million up 52% on pcp

 

 

 

Canada



Q1 sales AUD$0.0 million down 92% on pcp

 

 

 

USA



Q1 sales AUD$0.4 million up 44% on pcp

MELBOURNE, Australia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.

Continued growth (+34% on pcp) in Australia can be contributed to: (1) increased awareness and consideration driven by extensive digital and social media marketing. ...